NANOVERY is a United Kingdom-based startup that specializes in nucleic acid quantification using nanorobots. The company, founded in 2018, focuses on developing DNA nanorobots for the rapid and highly sensitive detection of challenging biomarkers. Their innovative approach has garnered significant attention from investors, with their most recent £1.06M Venture Round investment coming on 05 April 2023. This round of funding saw participation from JR Holding and the North East Innovation Fund, highlighting the confidence that prominent investment firms have in NANOVERY's potential for growth and impact in the biotech industry.
NANOVERY
Nanovery - experts in nucleic acid quantification using DNA nanorobots.
Founded 2018
Newcastle Upon Tyne, United Kingdom
14 employees
Venture round
Total: $3.12M
AI, Health Care +1
Newcastle Upon Tyne, United Kingdom
14 employees
Venture round
Total: $3.12M
AI, Health Care +1
General Information
Company Name
NANOVERY
Founded Year
2018
Location
Newcastle Upon Tyne, United Kingdom
Newcastle Upon Tyne, United Kingdom
Employees
14
Industries
AI, Health Care, Medical Devices
Funding Stage
Venture round
BounceWatch is an independent company data service, not affiliated with NANOVERY. To contact NANOVERY, visit nanovery.co.uk.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United Kingdom Market
About NANOVERY
Taxonomy: nanotechnology, biomedical engineering, diagnostic technology, DNA nanorobots, biomarker detection, medical robotics, disease diagnosis, nanorobotics, medical innovation
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | £1.06M | 2 |
|
05 Apr 2023 |
| Grant | £750.00K | 1 |
|
05 Apr 2023 |
| Series A | £835.00K | 2 |
|
07 Nov 2022 |
| Seed Round | £475.00K | 3 |
|
05 Apr 2021 |
NANOVERY Alternatives & Competitors
View All Alternatives
NANOVERY vs
Tangen Biosciences, Inc.
United States
The next generation in molecular diagnostics
Series A
6 employees
Biotechnology, Health Care
NANOVERY vs
etherna
Belgium
Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be
Series B
97 employees
Biotechnology, Health Care
NANOVERY vs
EMPE Diagnostics
Sweden
Confirmatory precision diagnostics for tuberculosis (MDR/XDR-TB) within 3 h even at resource-limited...
Series A
27 employees
Biotechnology, Health Care
FAQ About NANOVERY
Nanovery - experts in nucleic acid quantification using DNA nanorobots.
NANOVERY was founded in 2018.
NANOVERY is headquartered in Newcastle Upon Tyne, United Kingdom.
NANOVERY operates in AI, Health Care and Medical Devices. Its work centres on nanotechnology, biomedical engineering, diagnostic technology and DNA nanorobots.
NANOVERY has approximately 14 employees.
NANOVERY has completed 4 funding rounds, raising a total of $3.12M. The latest funding stage is Venture round.
Top alternatives and competitors to NANOVERY include Tangen Biosciences, Inc., etherna, EMPE Diagnostics, Genomtec SA, Craif Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NANOVERY and Tangen Biosciences, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for NANOVERY, https://bouncewatch.com/company/nanovery, updated 24 October 2024. When citing, please name BounceWatch and link this page.
